Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
QUESTION: In patients with fistulising or treatment-resistant Crohn’s disease, is infliximab safe and effective?
Studies were identified by searching Medline, EMBASE/Excerpta Medica, Current Contents, CINAHL, HealthSTAR, TOXLINE, the Cochrane Library, Drug Info Full Text, Pharmaceutical & Health Care Industry News, PharmaProjects, and Pharmaceutical News Index (1990 to May 2001). Scientific meeting abstracts were searched; major clinical gastroenterology journals were hand searched (to August 2001); and authors, government agencies, and pharmaceutical companies were contacted.
2 reviewers independently selected English-language randomised controlled trials (RCTs) that reported clinical end points for infliximab treatment in adults with fistulising or treatment-resistant Crohn’s disease.
2 independent reviewers extracted data on study centres, source of funding, …
Source of funding: not stated.
For correspondence: Dr J K Marshall, McMaster University, Hamilton, ON, Canada. Email.